The Peroxisome Proliferator-Activated Receptor γ Agonist Pioglitazone Improves Cardiometabolic Risk and Renal Inflammation in Murine Lupus
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Individuals with systemic lupus erythematosus (SLE) have a striking increase in the risk of premature atherosclerosis, a complication preceded by significant subclinical vascular damage. A proposed mechanism leading to accelerated vascular disease in SLE is an imbalance between vascular damage and repair, as patients with this disease display significant abnormalities in phenotype and function of endothelial progenitor cells. In addition, individuals with SLE have a higher incidence of insulin resistance which may further contribute to the increased cardiovascular risk. This study examined the role of the peroxisome proliferator activated receptor γ agonist pioglitazone in improving endothelial function, endothelial progenitor cell numbers and functional capacity, metabolic parameters, and disease activity in the lupus-prone murine model New Zealand Black/New Zealand White (NZB × NZW)F1. Ten-week-old prenephritic female NZB/NZW F1 mice were exposed to 10 or 25 mg/kg/day of oral pioglitazone or vehicle for 15 or 24 wk. Mice exposed to pioglitazone exhibited pronounced enhancement in endothelial-dependent vasorelaxation of thoracic aortas and in endothelial progenitor cell function, as assessed by the capacity of bone marrow-derived endothelial progenitor cells to differentiate into mature endothelial cells. Pioglitazone-treated mice showed improvement in insulin resistance, adipokine, and lipid profile. Kidneys from pioglitazone-treated mice showed significant decreases in immune complex deposition, renal inflammation, T cell glomerular infiltration, and intrarenal synthesis of TNF-α, IL-1β, and VCAM-1. These results indicate that peroxisome proliferator-activated receptor γ agonists could serve as important tools in the prevention of premature cardiovascular disease and organ damage in SLE.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The mechanisms of action of PPARs
Berger, J., & Moller, D. E. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104018 · Cited by 2,659
Circulating endothelial progenitor cells and cardiovascular outcomes
Werner, N., Kosiol, S., Schiegl, T., Ahlers, P., Walenta, K., Link, A., Böhm, M., & Nickenig, G. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043814 · Cited by 2,048
Close Relation of Endothelial Function in the Human Coronary and Peripheral Circulations
Anderson, T. J., Uehata, A., Gerhard, M. D., Meredith, I. T., Knab, S., Delagrange, D., Lieberman, E. H., Ganz, P., Creager, M. A., Yeung, A. C., et al. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00327-4 · Cited by 2,033 · cited 1×
“Therefore, finding strategies that prevent or improve endothelial dysfunction (a strong predictor of atherosclerosis development (51, 52)) and decrease metabolic abnormalities associated with premature vascular damage are considered an important priority in the health care of this patient population.”
BackgroundYki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Cnop, M., Havel, P. J., Utzschneider, K. M., Carr, D. B., Sinha, M. K., Boyko, E. J., Retzlaff, B. M., Knopp, R. H., Brunzell, J. D., & Kahn, S. E. (2003) · Diabetologia · doi:10.1007/s00125-003-1074-z · Cited by 1,483
Delerive, P., De Bosscher, K., Besnard, S., Vanden Berghe, W., Peters, J. M., Gonzalez, F. J., Fruchart, J.-C., Tedgui, A., Haegeman, G., & Staels, B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.45.32048 · Cited by 1,089
Feedback control of cyclooxygenase-2 expression through PPARγ
Inoue, H., Tanabe, T., & Umesono, K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001387200 · Cited by 276
Cited by
Anti-inflammatory Agents: Present and Future
Dinarello, C. A. (2010) · Cell · doi:10.1016/j.cell.2010.02.043 · Cited by 1,095
Anti-inflammatory activity of natural dietary flavonoids
Pan, M.-H., Lai, C.-S., & Ho, C.-T. (2010) · Food & Function · doi:10.1039/c0fo00103a · Cited by 605
Drugging the efferocytosis process: concepts and opportunities
Mehrotra, P., & Ravichandran, K. S. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00470-y · Cited by 459
Mitochondrial control of immunity: beyond ATP
Mehta, M. M., Weinberg, S. E., & Chandel, N. S. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.66 · Cited by 396
Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus
Knight, J. S., Zhao, W., Luo, W., Subramanian, V., O’Dell, A. A., Yalavarthi, S., Hodgin, J. B., Eitzman, D. T., Thompson, P. R., & Kaplan, M. J. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67390 · Cited by 389
Self-citationT cell metabolism: new insights in systemic lupus erythematosus pathogenesis and therapy
Sharabi, A., & Tsokos, G. C. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0356-x · Cited by 290
Majer, O., Bourgeois, C., Zwolanek, F., Lassnig, C., Kerjaschki, D., Mack, M., Müller, M., & Kuchler, K. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002811 · Cited by 156
Role of PPAR, LXR, and PXR in epidermal homeostasis and inflammation
Schmuth, M., Moosbrugger-Martinz, V., Blunder, S., & Dubrac, S. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2013.11.012 · Cited by 100
Metadata
- Authors
- Zhao, W., Thacker, S. G., Hodgin, J. B., Zhang, H., Wang, J. H., Park, J. L., Randolph, A., Somers, E. C., Pennathur, S., Kretzler, M., Brosius, F. C., & Kaplan, M. J.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-08
- Volume
- 183
- Issue
- 4
- Pages
- 2729-2740
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2168005454
- Cited by
- 58
- References
- 7
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.